In addition to PSMA targeting with J591, another potential target investigated for the delivery of 213Bi is the plasminogen activator inhibitor type 2 (PAI2) protein, known to be overexpressed on prostate cancer cells. Here, FOLH1 is linked to prostate carcinoma.